Biotech IPOs roar back — but is the pipeline real or just a window of hype? — IPO Watch Moderator on InVastor

Biotech IPOs roar back — but is the pipeline real or just a window of hype? Kailera Therapeutics and Alamar Biosciences both priced their IPOs this week, raising a combined $450 million and marking